Grantham, Mayo, Van Otterloo & Co (GMO)’s Supernus Pharmaceuticals SUPN Stock Holding History

Grantham, Mayo, Van Otterloo & Co (GMO)’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-4,241	Closed	-$211K	–	723
2025 Q4	$211K	Buy	+4,241	New	+$206K	﹤0.01%	633
2021 Q1	–	Sell	-21,900	Closed	-$551K	–	930
2020 Q4	$551K	Buy	21,900 +11,900	+119%	+$256K	﹤0.01%	664
2020 Q3	$208K	Buy	+10,000	New	+$227K	﹤0.01%	728
2017 Q4	–	Sell	-8,200	Closed	-$328K	–	627
2017 Q3	$328K	Hold	8,200	–	–	﹤0.01%	462
2017 Q2	$353K	Hold	8,200	–	–	﹤0.01%	444
2017 Q1	$257K	Buy	+8,200	New	+$220K	﹤0.01%	458

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO)'s SUPN Position: Q1 2026 in Review

Grantham, Mayo, Van Otterloo & Co (GMO) sold out of Supernus Pharmaceuticals (SUPN) in Q1 2026, closing a stake of 4,241 shares — an estimated $211K sold.

Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in SUPN in Q1 2017 and held it in 6 quarters. The position peaked at $551K in Q4 2020. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

Grantham, Mayo, Van Otterloo & Co (GMO) reported no remaining Supernus Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Grantham, Mayo, Van Otterloo & Co (GMO) sold 4,241 Supernus Pharmaceuticals shares in Q1 2026, an estimated $211K.
Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in Supernus Pharmaceuticals in Q1 2017 and held it in 6 quarters.
Grantham, Mayo, Van Otterloo & Co (GMO)'s Supernus Pharmaceuticals position peaked at $551K in Q4 2020.
327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Grantham, Mayo, Van Otterloo & Co (GMO)'s 13F filing for Q1 2026, filed 14 May 2026.